This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.

Clinical Leadership

Unsurpassed Clinical Leadership to Transform Cancer Outcomes | Genomic Health, Inc.

Unsurpassed Scientific and Clinical Expertise to Transform
Cancer Outcomes

Genomic Health pioneered the field of genomic cancer diagnostics with the bold vision of analysing the biology of a patient’s tumour to improve the quality of treatment decisions and long-term outcomes. By dedicating ourselves to the development of practice-changing genomic tests, we are leading the effort to eliminate the “one-size-fits-all” therapeutic approach to cancer that often results in either over- or under-treatment.

When we introduced our first product, the Oncotype DX® breast cancer test, in 2004, not only did we address the need to identify the small percentage of patients with early-stage disease who will truly benefit from chemotherapy, we also established a new paradigm for the development of genomic-based diagnostic tests that empower doctors and patients to personalise and optimise treatment planning.

As the first step in developing tests that can answer critical questions about individual cancers, we conduct sophisticated studies to help us understand which patterns of gene expression within a tumour are linked to the likelihood of the cancer returning or spreading, or to a response to a specific cancer therapy. Each test is aimed at answering an important clinical question, such as:

  • Do I need chemotherapy? (invasive breast cancer)
  • Do I need surgery? (prostate cancer)
  • Do I need additional treatment after surgery (DCIS breast cancer)
  • Do I have aggressive cancer? (stage II/III colon cancer)

We then work with collaborators to carefully design and conduct multiple studies in large, relevant patient populations to validate each test from a clinical and analytical perspective. These studies generate reproducible data that is presented and published in peer-reviewed settings. We also conduct clinical utility studies that consistently demonstrate to doctors, patients, and trusts that our tests are positively impact treatment decisions and provide significant benefit, both from a patient outcome and cost perspective.

The rigour of our approach has resulted in an unparalleled track record; we have achieved more than 155 peer-reviewed publications and conducted more than 100 successful clinical studies in more than 65,000 breast, colon and prostate cancer patients. This growing body of scientific and clinical evidence has driven the success of our tests in making cancer care smarter and improving patient outcomes.